We are live on ! Find out more
BIVV

Bioverativ Inc. Common Stock
BIVV

Delisted

BIVV was delisted on the 8th of March, 2018.

Back to rankings

2 hedge funds and large institutions have $27K invested in Bioverativ Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 449 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 459 → 2 (-457)

100% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 449

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $5.76B → $27K (-$5.76B)

Holders
2
Holders Change
-457
Holders Change %
-99.56%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
449
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACS
Archford Capital Strategies
Illinois
+$2.28K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$585M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$497M
3
Primecap Management
Primecap Management
California
-$411M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$274M
5
State Street
State Street
Massachusetts
-$232M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
$26K – – –
ACS
2
Archford Capital Strategies
Illinois
$1K +$2.28K +25 New
BlackRock
3
BlackRock
New York
– -$585M -10,845,635 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$497M -9,226,008 Closed
Primecap Management
5
Primecap Management
California
– -$411M -7,622,324 Closed
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
– -$274M -5,087,776 Closed
State Street
7
State Street
Massachusetts
– -$232M -4,306,019 Closed
ClearBridge Investments
8
ClearBridge Investments
New York
– -$205M -3,801,486 Closed
HM
9
HealthCor Management
New York
– -$202M -3,750,000 Closed
EIG
10
EdgePoint Investment Group
Ontario, Canada
– -$174M -3,230,809 Closed
Fidelity Investments
11
Fidelity Investments
Massachusetts
– -$137M -2,535,389 Closed
JIM
12
Jupiter Investment Management
United Kingdom
– -$135M -2,507,002 Closed
JSP
13
Jackson Square Partners
California
– -$114M -2,107,110 Closed
WIM
14
Woodford Investment Management
United Kingdom
– -$105M -1,948,325 Closed
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
– -$104M -1,927,374 Closed
AQR Capital Management
16
AQR Capital Management
Connecticut
– -$94.9M -1,760,862 Closed
Wells Fargo
17
Wells Fargo
California
– -$91.9M -1,705,186 Closed
Norges Bank
18
Norges Bank
Norway
– -$84.1M -1,559,061 Closed
PI
19
Putnam Investments
Massachusetts
– -$79.7M -1,477,681 Closed
Janus Henderson Group
20
Janus Henderson Group
United Kingdom
– -$78.6M -1,457,583 Closed
O
21
OppenheimerFunds
New York
– -$77.3M -1,434,200 Closed
Bank of New York Mellon
22
Bank of New York Mellon
New York
– -$74.5M -1,382,422 Closed
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
– -$67.2M -1,246,815 Closed
SCM
24
Sarissa Capital Management
Connecticut
– -$62.8M -1,165,000 Closed
Goldman Sachs
25
Goldman Sachs
New York
– -$61.7M -1,143,890 Closed
1
2 3 4 5

BIVV Hedge Fund Activity: Q1 2018 in Review

2 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q1 2018, worth a combined $27K — down 100% from $5.76B a quarter earlier.

Sellers outnumbered buyers: 449 funds closed out of BIVV and 1 opened new positions — a net loss of 448 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Archford Capital Strategies, opening a new position worth an estimated $2.28K. The largest seller was BlackRock, exiting entirely with an estimated $585M sold.

  • 2 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q1 2018, down from 459 in Q4 2017.
  • Funds reported $27K of Bioverativ Inc. Common Stock stock for Q1 2018, down 100% quarter-over-quarter.
  • 1 fund opened new Bioverativ Inc. Common Stock positions in Q1 2018 and 449 closed out, a net change of -448 holders.
  • The largest Bioverativ Inc. Common Stock buyer in Q1 2018 was Archford Capital Strategies, an estimated $2.28K added.
  • The largest Bioverativ Inc. Common Stock seller in Q1 2018 was BlackRock, an estimated $585M sold.

Based on aggregated 13F filings for Q1 2018.